• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PLT012，一种人源化抗CD36抗体，对释放针对肝癌和肝转移的抗肿瘤免疫有效。

PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis.

作者信息

Tzeng Sheue-Fen, Yu Yi-Ru, Park Jaeoh, von Renesse Janusz, Hsiao Huey-Wen, Hsu Chen-Hsuan, Garnica Josep, Chen Jintian, Chiu Lu-Ting, Santol Jonas, Chen Tse-Yu, Chung Pei-Han, Kandalaft Lana E, Starlinger Patrick, Hsieh Rodney Cheng-En, Yu Ming-Chin, Hsiao Pei-Wen, Carmona Santiago J, Chen Hung-Kai, Meng Zhen, Lin Yun-Han, Zhou Jingying, Tsai Chin-Hsien, Ho Ping-Chih

机构信息

Tumor Immune Analysis Core, Office of Research & Development, Taipei Medical University, Taipei, Taiwan.

Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan.

出版信息

Cancer Discov. 2025 Apr 28:OF1-OF21. doi: 10.1158/2159-8290.CD-24-1409.

DOI:10.1158/2159-8290.CD-24-1409
PMID:40294022
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7617665/
Abstract

Despite the success of cancer immunotherapies, like immune checkpoint inhibitors, many patients still fail to demonstrate significant responses because of metabolic constraints in tumors. PLT012 rejuvenates antitumor immunity by targeting metabolic pathways to reprogram the immune landscape of liver cancer and liver metastasis, with potential to influence future HCC immunotherapy.

摘要

尽管癌症免疫疗法取得了成功，如免疫检查点抑制剂，但由于肿瘤中的代谢限制，许多患者仍未能表现出显著反应。PLT012通过靶向代谢途径来重塑肝癌和肝转移的免疫格局，从而恢复抗肿瘤免疫力，有可能影响未来的肝癌免疫治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17a3/7617665/cd6cacff5b4f/EMS204816-f007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17a3/7617665/241330a09e4e/EMS204816-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17a3/7617665/f4f3ede806c2/EMS204816-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17a3/7617665/2889d6582093/EMS204816-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17a3/7617665/aea274dc5618/EMS204816-f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17a3/7617665/6747548845c9/EMS204816-f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17a3/7617665/7260826246e2/EMS204816-f006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17a3/7617665/cd6cacff5b4f/EMS204816-f007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17a3/7617665/241330a09e4e/EMS204816-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17a3/7617665/f4f3ede806c2/EMS204816-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17a3/7617665/2889d6582093/EMS204816-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17a3/7617665/aea274dc5618/EMS204816-f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17a3/7617665/6747548845c9/EMS204816-f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17a3/7617665/7260826246e2/EMS204816-f006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17a3/7617665/cd6cacff5b4f/EMS204816-f007.jpg

相似文献

1
PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis.PLT012，一种人源化抗CD36抗体，对释放针对肝癌和肝转移的抗肿瘤免疫有效。
Cancer Discov. 2025 Apr 28:OF1-OF21. doi: 10.1158/2159-8290.CD-24-1409.
2
Liensinine reshapes the immune microenvironment and enhances immunotherapy by reprogramming metabolism through the AMPK-HIF-1α axis in hepatocellular carcinoma.莲心碱通过激活腺苷酸活化蛋白激酶-低氧诱导因子-1α轴重编程代谢，重塑免疫微环境并增强肝细胞癌的免疫治疗效果。
J Exp Clin Cancer Res. 2025 Jul 15;44(1):208. doi: 10.1186/s13046-025-03477-6.
3
Oncolytic reovirus enhances the effect of CEA immunotherapy when combined with PD1-PDL1 inhibitor in a colorectal cancer model.在结直肠癌模型中，溶瘤呼肠孤病毒与PD1-PDL1抑制剂联合使用时可增强CEA免疫疗法的效果。
Immunotherapy. 2025 Apr;17(6):425-435. doi: 10.1080/1750743X.2025.2501926. Epub 2025 May 12.
4
Serotonin receptor 5-HT as a potential target for HCC immunotherapy.血清素受体5-HT作为肝癌免疫治疗的潜在靶点。
J Immunother Cancer. 2025 Jun 23;13(6):e011088. doi: 10.1136/jitc-2024-011088.
5
Tumor-suppressing multi-enterobacteria and PD-1/PD-L1 immune checkpoint inhibitor combination improves the outcome of hepatocellular carcinoma therapy.抑癌多肠道细菌与PD-1/PD-L1免疫检查点抑制剂联合应用可改善肝细胞癌治疗效果。
Front Immunol. 2025 Jun 20;16:1598436. doi: 10.3389/fimmu.2025.1598436. eCollection 2025.
6
Targeting USP47 enhances immunotherapy in hepatocellular carcinoma by destabilizing PD-L1.靶向USP47通过使PD-L1不稳定增强肝细胞癌的免疫治疗效果。
Int Immunopharmacol. 2025 Aug 28;161:115024. doi: 10.1016/j.intimp.2025.115024. Epub 2025 Jun 9.
7
Nanoliposomal PD-1 antagonist target tumor-draining lymph nodes to revitalize T cells and improve anti-tumor effect in hepatocellular carcinoma.纳米脂质体PD-1拮抗剂靶向肿瘤引流淋巴结以激活T细胞并增强肝癌的抗肿瘤效果。
J Nanobiotechnology. 2025 Jul 30;23(1):549. doi: 10.1186/s12951-025-03537-1.
8
CD36 Promotes Iron Accumulation and Dysfunction in CD8+ T Cells via the p38-CEBPB-TfR1 Axis in Early-stage Hepatocellular Carcinoma.CD36通过p38-CEBPB-TfR1轴促进早期肝细胞癌中CD8+ T细胞的铁积累和功能障碍。
Clin Mol Hepatol. 2025 Mar 4. doi: 10.3350/cmh.2024.0948.
9
Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.肝纤维化通过 GOLM1 介导的 PD-L1 上调促进肝癌中的免疫逃逸。
Cancer Lett. 2021 Aug 10;513:14-25. doi: 10.1016/j.canlet.2021.05.007. Epub 2021 May 14.
10
Ganoderic acid A regulates CSF1R to reprogram tumor-associated macrophages for immune therapy of hepatocellular carcinoma.灵芝酸A通过调节集落刺激因子1受体对肿瘤相关巨噬细胞进行重编程，用于肝细胞癌的免疫治疗。
Int Immunopharmacol. 2025 Aug 28;161:114989. doi: 10.1016/j.intimp.2025.114989. Epub 2025 Jun 7.

引用本文的文献

1
Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer.鉴定新型选择性CD36抑制剂以增强HER2阳性乳腺癌的HER2靶向治疗效果。
Sci Rep. 2025 Aug 6;15(1):28709. doi: 10.1038/s41598-025-14639-z.

本文引用的文献

1
PPARβ/δ-orchestrated metabolic reprogramming supports the formation and maintenance of memory CD8 T cells.过氧化物酶体增殖物激活受体β/δ（PPARβ/δ）调控的代谢重编程支持记忆 CD8 T 细胞的形成和维持。
Sci Immunol. 2024 Aug 23;9(98):eadn2717. doi: 10.1126/sciimmunol.adn2717.
2
Circulating fatty acids and risk of hepatocellular carcinoma and chronic liver disease mortality in the UK Biobank.循环脂肪酸与英国生物库中肝细胞癌和慢性肝病死亡率的关系
Nat Commun. 2024 May 2;15(1):3707. doi: 10.1038/s41467-024-47960-8.
3
Obesity-related T cell dysfunction impairs immunosurveillance and increases cancer risk.
肥胖相关的 T 细胞功能障碍会损害免疫监视并增加癌症风险。
Nat Commun. 2024 Apr 2;15(1):2835. doi: 10.1038/s41467-024-47359-5.
4
Regulatory T cell: a double-edged sword from metabolic-dysfunction-associated steatohepatitis to hepatocellular carcinoma.调节性 T 细胞：从代谢功能障碍相关脂肪性肝炎到肝细胞癌的双刃剑。
EBioMedicine. 2024 Mar;101:105031. doi: 10.1016/j.ebiom.2024.105031. Epub 2024 Feb 23.
5
Fatty acid metabolism of immune cells: a new target of tumour immunotherapy.免疫细胞的脂肪酸代谢：肿瘤免疫治疗的新靶点。
Cell Death Discov. 2024 Jan 20;10(1):39. doi: 10.1038/s41420-024-01807-9.
6
Immunosurveillance encounters cancer metabolism.免疫监视遭遇癌症代谢。
EMBO Rep. 2024 Feb;25(2):471-488. doi: 10.1038/s44319-023-00038-w. Epub 2024 Jan 12.
7
CD36 maintains lipid homeostasis via selective uptake of monounsaturated fatty acids during matrix detachment and tumor progression.CD36 通过在基质脱离和肿瘤进展过程中选择性摄取单不饱和脂肪酸来维持脂质稳态。
Cell Metab. 2023 Nov 7;35(11):2060-2076.e9. doi: 10.1016/j.cmet.2023.09.012. Epub 2023 Oct 17.
8
Regulatory circuits of mitophagy restrict distinct modes of cell death during memory CD8 T cell formation.自噬调控回路限制记忆性 CD8 T 细胞形成过程中不同的细胞死亡方式。
Sci Immunol. 2023 Sep 29;8(87):eadf7579. doi: 10.1126/sciimmunol.adf7579. Epub 2023 Sep 22.
9
Extending support for mouse data in the Molecular Signatures Database (MSigDB).扩展对分子特征数据库（MSigDB）中鼠标数据的支持。
Nat Methods. 2023 Nov;20(11):1619-1620. doi: 10.1038/s41592-023-02014-7.
10
Identification of pre-diagnostic lipid sets associated with liver cancer risk using untargeted lipidomics and chemical set analysis: A nested case-control study within the ATBC cohort.利用非靶向脂质组学和化学物质集分析鉴定与肝癌风险相关的预诊断脂质标志物：在 ATBC 队列中进行的嵌套病例对照研究。
Int J Cancer. 2024 Feb 1;154(3):454-464. doi: 10.1002/ijc.34726. Epub 2023 Sep 11.